Yi Sang sold $413K of ZBH

Yi Sang (Group President, Asia Pacific) sold 5,000 shares of ZIMMER BIOMET HOLDINGS, INC. (ZBH) at an average of $82.64 ($82.64–$82.66, $0.41M total) across 2 trades on 2026-05-29.

Original reporting
SEC EDGAR · Yi Sang
Published Jun 2, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ZBH
Bearish
low confidence
Mentioned
$ZBH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZBHBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing; not necessarily a negative outlook.

Relevance 4/10Novelty 3/10Timing: after-hours filing

Background

SEC Form 4 filing reports an insider transaction for Zimmer Biomet Holdings.

Company-level read

Ticker impact

$ZBHBearishLow confidence
Context

Form 4 disclosed Group President Yi Sang sold 5,000 shares for $413,216, a routine insider sale.

Expected impact

likely modest pressure as the market prices in the insider sale

Evidence & confidence

Sale size is small relative to market cap and no 10b5-1 plan; investors typically view such sales as neutral to mildly negative.

Market effects

Minimal impact on medical device sector; insider activity is routine.

No regional effect; isolated to ZBH.

Low global relevance.

Counterpoint

The sale could be a signal of insider concern, but size is too small to warrant a trade.

Key entities

  • Zimmer Biomet Holdings, Inc.

    Medical device manufacturer listed on NYSE (ZBH).

  • Yi Sang

    Group President, Asia Pacific.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.